The effect of hepatic steatosis on Peginterferon alfa-2b and Ribavirin combination therapy for chronic hepatitis C

DOI Web Site Web Site 2 Citations 48 References
  • Notsumata Kazuo
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Tomita Shunji
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Sanada Taku
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Kosaka Shotaro
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Toya Daishu
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Tanaka Nobuyosi
    Department of Internal Medicine, Fukuiken Saiseikai Hospital
  • Sudo Yoshiko
    Department of Pathology, Fukuiken Saiseikai Hospital
  • Zen You
    Department of Hospital Pathology, Kanazawa Medical University School of Medicine

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎に対するＰｅｇｉｎｔｅｒｆｅｒｏｎ　ａｌｆａ－２ｂ，　Ｒｉｂａｖｉｒｉｎ併用療法における肝脂肪変性の関与について
  • Cガタ マンセイ カンエン ニ タイスル Peginterferon alfa 2b Ribavirin ヘイヨウ リョウホウ ニ オケル カン シボウ ヘンセイ ノ カンヨ ニ ツイテ

Search this article

Abstract

Factors determining the SVR (sustained virological response) with PegIFN (peginterferon alfa-2b) and RBV (ribavirin) combination therapy were explored in 202 chronic hepatitis C patients (168 genotype 1 and 34 genotype 2) with high levels of circulating virus. A SVR assessed by ITT (intention-to-treat) analysis was observed in 41.1% of genotype 1 group and 76.5% of genotype 2 group. Factors influencing the SVR of genotype 1 were age, hepatic steatosis and response to prior IFN and RBV combination therapy. The SVR of genotype 1 differed significantly between the hepatic steatosis positive group (30.5%) and the negative group (61.1%) (p<0.001). The background variables influencing the presence of hepatic steatosis were FBS, IRI and HOMA-R but not BMI or lipid metabolism. The only factor influencing the SVR of genotype 2 was FBS. The SVR of genotype 2 did not differ significantly between the hepatic steatosis positive group (76.5%) and negative group (84.6%) (p=0.6725). These results seem to suggest that the hepatic steatosis is an important factor influencing the responses of genotype 1 to PegIFN and RBV combination therapy and the treatment of hepatic steatosis may be useful as a new strategy.<br>

Journal

  • Kanzo

    Kanzo 49 (5), 183-191, 2008

    The Japan Society of Hepatology

Citations (2)*help

See more

References(48)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top